Eledon Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 20
- Market Cap
- $113.4M
- Website
- http://eledon.com
- Introduction
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.
Tegoprubart Successfully Used in Second Pig-to-Human Kidney Xenotransplant at MGH
Massachusetts General Hospital successfully performed its second pig-to-human kidney transplant using Eledon's tegoprubart as a key immunosuppressant, with the patient now off dialysis after two years.
Eledon Pharmaceuticals' Tegoprubart Shows Promise in Transplantation Therapies
Eledon Pharmaceuticals completed Phase 2 BESTOW trial enrollment for tegoprubart in kidney transplantation, with topline results expected in Q4 2025.
Tegoprubart Shows Promise in Achieving Insulin Independence After Islet Transplantation
Initial data from a University of Chicago study show that tegoprubart, an anti-CD40L antibody, helped two out of three patients achieve insulin independence after islet transplantation.
Tegoprubart Shows Promise in Improving Islet Cell Transplant Outcomes for Type 1 Diabetes
Tegoprubart, an experimental immunosuppressant, demonstrates encouraging results in islet cell transplants for Type 1 diabetes, potentially reducing or eliminating the need for insulin injections.
Stem Cell Therapy Cures Type 1 Diabetes in Illinois Woman, Offering Hope for Functional Cure
Marlaina Goedel, a 30-year-old woman from Illinois, has been cured of type 1 diabetes after 25 years of insulin dependence through a pioneering islet cell transplant.
Eledon's Tegoprubart Shows Promise in Type 1 Diabetes Islet Transplantation
Eledon Pharmaceuticals' tegoprubart, as part of an immunosuppression regimen, enabled insulin independence in two of three type 1 diabetes subjects after islet transplantation.
Tegoprubart Shows Promise in Improving Islet Cell Transplant Outcomes for Type 1 Diabetes
Tegoprubart, an experimental immunosuppressant, demonstrates encouraging results in islet cell transplantation for Type 1 diabetes, potentially reducing or eliminating the need for insulin injections.
Eledon's Tegoprubart Shows Promise in Type 1 Diabetes Islet Transplantation
Eledon Pharmaceuticals reports that tegoprubart, as part of an immunosuppression regimen, enabled insulin independence in two of three type 1 diabetes subjects after islet transplantation.
Eledon's Tegoprubart Shows Promise in Type 1 Diabetes Islet Transplantation
Eledon Pharmaceuticals reports that tegoprubart, combined with an immunosuppression regimen, enabled insulin independence in two of three T1D subjects post-islet transplant.
Eledon Pharmaceuticals Completes Enrollment in Phase 2 BESTOW Trial of Tegoprubart for Kidney Transplant Rejection
Eledon Pharmaceuticals completed enrollment for its Phase 2 BESTOW trial of tegoprubart, an immunosuppression therapy, four months ahead of schedule.